Interleukin-24 (IL24) Is Suppressed by PAX3-FOXO1 and Is a Novel Therapy for Rhabdomyosarcoma
Open Access
- 1 December 2018
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 17 (12) , 2756-2766
Abstract
Alveolar rhabdomyosarcoma (ARMS) patients have a poor prognosis, and this is primarily due to overexpression of the oncogenic fusion protein PAX3-FOXO1. Results of RNA-sequencing studies show that PAX3-FOXO1 represses expression of interleukin-24 (IL24), and these two genes are inversely expressed in patient tumors. PAX3-FOXO1 also regulates histone deacetylase 5 (HDAC5) in ARMS cells, and results of RNA interference studies confirmed that PAX3-FOXO1–mediated repression of IL24 is HDAC5-dependent. Knockdown of PAX3-FOXO1 decreases ARMS cell proliferation, survival, and migration, and we also observed similar responses in cells after overexpression of IL24, consistent with results reported for this tumor suppressor–like cytokine in other solid tumors. We also observed in double knockdown studies that the inhibition of ARMS cell proliferation, survival, and migration after knockdown of PAX3-FOXO1 was significantly (>75%) reversed by knockdown of IL24. Adenoviral-expressed IL24 was directly injected into ARMS tumors in athymic nude mice, and this resulted in decreased tumor growth and weight. Because adenoviral IL24 has already successfully undergone phase I in clinical trials, this represents an alternative approach (alone and/or combination) for treating ARMS patients who currently undergo cytotoxic drug therapies.Keywords
All Related Versions
Funding Information
- NIH (P30-ES023512)
This publication has 45 references indexed in Scilit:
- Clinical Ascertainment of Health Outcomes Among Adults Treated for Childhood CancerJAMA, 2013
- PAX3/FOXO1 Fusion Gene Status Is the Key Prognostic Molecular Marker in Rhabdomyosarcoma and Significantly Improves Current Risk StratificationJournal of Clinical Oncology, 2012
- Alveolar rhabdomyosarcoma – The molecular drivers of PAX3/7-FOXO1-induced tumorigenesisSkeletal Muscle, 2012
- The nuclear receptor TR3 regulates mTORC1 signaling in lung cancer cells expressing wild-type p53Oncogene, 2011
- Regulation of Nur77 expression by β‐catenin and its mitogenic effect in colon cancer cellsThe FASEB Journal, 2010
- Inactivation of the Orphan Nuclear Receptor TR3/Nur77 Inhibits Pancreatic Cancer Cell and Tumor GrowthCancer Research, 2010
- Gene Expression Profiling for Survival Prediction in Pediatric Rhabdomyosarcomas: A Report From the Children's Oncology GroupJournal of Clinical Oncology, 2010
- Molecular Classification of Rhabdomyosarcoma—Genotypic and Phenotypic Determinants of DiagnosisThe American Journal of Pathology, 2009
- PAX3–FOXO1 fusion gene in rhabdomyosarcomaCancer Letters, 2008
- Caspase-, cathepsin-, and PERK-dependent regulation of MDA-7/IL-24-induced cell killing in primary human glioma cellsMolecular Cancer Therapeutics, 2008